Genetic testing has taken off and may usher in a new era of genetically tailored health care. Insurers are figuring out how to cope with the avalanche of information. Could genetic counselors as standalone practitioners be part of the answer?
It is finally starting to happen. The first gene therapy to treat an inherited disease is out of the gate. But my, that price tag: $850,000. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation? Outcomes-based pricing doesn’t really do the trick.
At first patients didn’t care that much. Then the monitors improved, and studies showed improved outcomes. But CMS wouldn’t cover them unless they had a ‘nonadjunctive’ indication. Now some envision a time when fingersticks will be a thing of the past for many people with diabetes.
The days of painful fingerpricks to measure blood sugar levels with glucometers finally may be over for many patients with diabetes, especially for the 1.2 million Americans with type 1 diabetes but also for at least 1.75 million patients with type 2 diabetes who control their condition by self-injecting…
Value-based agreements between insurers and drugmakers have gotten a lot of attention lately, but device makers, including those that make continuous glucose monitors, are also making deals with insurers that tie payment to how the device performs. Suzanne Winter Suzanne Winter, vice president of…
Asthma is a common chronic respiratory disease affecting nearly 8% of the U.S. population. Fractional exhaled nitric oxide (FeNO) is a noninvasive biomarker for T2-driven (i.e., allergic) airway inflammation that could be used to improve diagnosis, optimize inhaled corticosteroid dosing, and monitor adherence.
Current asthma guidelines combine treatment, follow-up, and re-evaluation to manage asthma control, reduce impairment, and decrease risk of morbidity in patients. Analysis reveals that FeNO monitoring to guide asthma management is cost effective, increasing quality-adjusted life years while decreasing costs associated with asthma management.